The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients

British Journal of Haematology

Volumn 160, Issue 2, 2013, Pages 269-271

  Katagiri, Seiichiro ^a   Umezu, Tomohiro ^a   Ohyashiki, Junko H ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

BCL2L11 deletion polymorphism; Chronic myeloid leukaemia; Complete molecular remission; Discontinuation of imatinib

Indexed keywords

BIM PROTEIN; GENOMIC DNA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

BCL2L11 GENE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMPLETE MOLECULAR RESPONSE; CYTOTOXIC T LYMPHOCYTE; DRUG WITHDRAWAL; FOLLOW UP; GENE DELETION; GENETIC POLYMORPHISM; HUMAN; IMMUNOSURVEILLANCE; LETTER; NATURAL KILLER CELL; PATIENT SAFETY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CHROMOSOME BANDING; DRUG ADMINISTRATION SCHEDULE; FUSION PROTEINS, BCR-ABL; HUMANS; INTRONS; JAPAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PIPERAZINES; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; SEQUENCE DELETION; TIME FACTORS;

EID: 84872232479     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12111     Document Type: Letter

References (8)

1. Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., Hochhaus, A., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Radich, J., Simonsson, B., Silver, R.T., Goldman, J & Hehmann, R; European LeukemiaNet. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27, 6041-6051.
2. Cortes, J., O'Brien, S. & Kantarjian, H. (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood, 104, 2204-2205.
3. + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceeding of the National Academy of Science of the United States of America, 103, 14907-14912.
4. Mahon, F.X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., Etienne, G., Reiffers, J. & Rousselot, P; Intergroupe Français des Leucémies Myéloïdes Croniques. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncology, 11, 1029-1035.
5. Ng, K.P., Hillmer, A.M., Chuah, C.T.H., Juan, W.C., Ko, T.K., Teo, A.S., Ariyaratne, P.N., Takahashi, N., Sawada, K., Fei, Y., Soh, S., Lee, W.H., Huang, J.W., Allen, Jr, J.C. ., Woo, X.Y., Nagarajan, N., Kumar, V., Thalamuthu, A., Poh, W.T., Ang, A.L., Mya, H.T., How, G.F., Yang, L.Y., Koh, L.P., Chowba, y B., Chang, C.T., Nadarajan, V.S., Chng, W.J., Than, H., Lim, L.C., Goh, Y.T., Zhang, S., Poh, D., Tan, P., See, t J.E., Ang, M.K., Chau, N.M., Ng, Q.S., Tan, D.S., Soda, M., Isobe, K., Nöthen, M.M., Wong, T.Y., Shahab, A., Ruan, X., Cacheux-Rataboul, V., Sung, W.K., Tan, E.H., Yatabe, Y., Mano, H., Soo, R.A., Chin, T.M., Lim, W.T., Ruan, Y. & Ong, S.T. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Medicine, 18, 521-528.
6. + T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. British Journal of Haematology, 157, 254-256.
7. Ross, D.M., Branford, S., Seymour, J.F., Schearer, A.P., Arthur, C., Bartley, P.A., Slader, C., Field, C., Dang, P., Filshie, R.J., Mills, A.K., Grigg, A.P., Melo, J.V. & Hughes, T.P. (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia, 24, 1719-1724.
8. Takahashi, N., Kyo, T., Maeda, Y., Sugihara, T., Usuki, K., Kawaguchi, T., Usui, N., Okamoto, S., Ohe, Y., Ohtake, S., Kitamura, K., Yamamoto, M., Teshima, H., Motoji, T., Tamaki, T., Sawada, K. & Ohyashiki, K. (2012) Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica, 97, 903-906.